Relay Therapeutics Inc. (NASDAQ:RLAY) reported initial Phase 2 data for zovegalisib in patients with vascular anomalies, with the company highlighting lesion reduction, symptom improvement, and a safety profile that may support long-term treatment use.
Vascular anomalies are a group of rare disorders characterized by abnormal development of blood vessels, lymphatic vessels, and surrounding tissues.
Something went wrong.
Early Data Showed Lesion Reduction Across Patients
As of the April 15, 2026, data cutoff, 60% of response-evaluable patients achieved a volumetric response at the first MRI assessment conducted after 12 weeks of treatment.
